Announcement on Preliminary Earnings Estimate for 2024
Filed with SSE · · 3 pages · Chinese
Jiangsu Yahong Meditech Co., Ltd. on 6ix
Earlier from Jiangsu Yahong Meditech
- Announcement on Voluntary Disclosure on Phase II Clinical Trial Data of Oral APL-1202 Combined with Tislelizumab in Neoadjuvant Therapy for Muscle-invasive Bladder Cancer at the 2025 American Society of Clinical Oncology (ASCO) Genitourinary Cancer Symposium
- Announcement on Adjustment of Core Technical Personnel
- Announcement on Opening Special Settlement Accounts for the Cash Management of Raised Funds
- Announcement on Using Some Temporarily Idle Raised Funds for Cash Management
- Announcement on the Voluntary Disclosure of the Approval of the Clinical Trial Application for APL-2302 by the National Medical Products Administration
Later from Jiangsu Yahong Meditech
- Announcement on Voluntary Disclosure Regarding the Completion of First Subject Enrollment in Phase Ⅰa Clinical Trial for APL-2302
- Special Report on Deposit and Actual Use of Raised Funds in 2024
- Announcement on Attending the 2024 SSE STAR Market Innovative Drug Industry Collective Performance Briefing and Q1 2025 Performance Briefing
- Report for Q1 2025
- Announcement on Resolution of the 2024 Annual General Meeting
Follow Jiangsu Yahong Meditech into a list and get an email when it puts out news.
Follow Jiangsu Yahong Meditech